Equillium's Total Assets for the quarter that ended in Sep. 2024 was $34.46 Mil.
During the past 12 months, Equillium's average Total Assets Growth Rate was -3.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 43.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 49.10% per year.
During the past 7 years, Equillium's highest 3-Year average Total Assets Growth Rate was 311.10%. The lowest was 43.60%. And the median was 50.50%.
Total Assets is connected with ROA %. Equillium's annualizedROA % for the quarter that ended in Sep. 2024 was -0.07%. Total Assets is also linked to Revenue through Asset Turnover. Equillium's Asset Turnover for the quarter that ended in Sep. 2024 was 0.31.
Equillium Total Assets Historical Data
The historical data trend for Equillium's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Equillium's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Equillium's Asset Turnover for the quarter that ended in Sep. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Equillium Total Assets Related Terms
Thank you for viewing the detailed overview of Equillium's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EQ has been successfully added to your 